Episode 5: Scaling the Access Wall — Real-World Evidence as a DifferentiatorIn episode 5, we explore how real-world evidence (RWE) has become the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations. We compare how leading severe-asthma brands deploy RWE today (e.g., registry analyses, integrated claims/EMR studies, regional dashboards) and outline Lumara’s options nine to twelve months pre-launch: claims/EMR partnerships, a purpose-built observational cohort, peer-reviewed publications and reprints, and interactive budget-impact tools for field teams. We also highlight what plans expect: local relevance, layered storytelling (trials + RWE + cost modeling), conservative framing, and scenario analysis.What you’ll learnHow plans weigh RWE vs. trial data in tiering and renewalsWhich data sources and partnerships move the needle (claims/EMR, registries, payer dashboards)How to localize insights for Commercial, Medicare Part D, Medicaid, and regional MCOsWays to embed RWE in AMCP dossiers and access tools—without overclaimingPractical guardrails: transparency, bias, and connecting efficacy to observed practiceFeatured segmentsWhat Counts as “Real” for Payers?Build the RWE Stack: Partnerships, Cohorts, and DashboardsFrom Evidence to Access: Playbook, KPIs, and Guardrails

Ver todos los episodios